This page shows the latest cell and gene therapy news and features for those working in and with pharma, biotech and healthcare.
The new cell and gene therapy platform will house both AskBio and another of Bayer’s recently acquired firms, BlueRock Therapeutics, under one roof. ... The company also said that it has a ‘vibrant’ cell and gene therapy pipeline with five advanced
Acquisition will expand Bayers’s pipeline with preclinical/clinical candidates. Bayer has announced its acquisition of Asklepios BioPharmaceutical (AskBio) to bolster its presence in cell and gene therapy, paying up to ... Germany-based Bayer will pay
guidance and allow existing recommendations to be updated more quickly, said the agency. ... That update is intended to take into account developments such as personalised medicine, digitisation of health and use of cell and gene therapy.
Novartis acquired the gene therapy specialist AveXis in April last year and Zolgensma had been subsequently developed by them. ... There had already been concerns over how commercially sustainable the field of cell and gene therapy is, with Zolgensma’s
He added: “NICE is undertaking this review at a time of unprecedented change in the healthcare system, where developments such as personalised medicine, digitalisation of health, and use of cell and ... gene therapy, mean products are becoming ever
a potential flood of new cell and gene therapy products. ... Also eyecatching were Woodcock’s comments on two high profile FDA approvals of spinal muscular atrophy (SMA) treatments, Biogen’s Spinraza and Novartis’ gene therapy Zolgensma.
More from news
Approximately 41 fully matching, plus 44 partially matching documents found.
Often lumped together as terms, the key difference between cell therapy and gene therapy is that the former utilises cells from a donor or the patient themselves to treat a disease ... The cell therapy, gene therapy and tissue engineering sector raised $2
Takeda’s Asit Parikh talks about a game changer for IBD patients and the company’s long-term strategy for gene and cell therapy. ... Takeda’s strategy is to develop GI products that address the highest unmet needs, which includes projects across
The Cell and Gene Therapy Catapult is also continuing to work to bridge the gap between ‘translational’ research and commercialisation. ... to cell and tissue requirements.
The number of companies targeting the development of new cell and gene therapies has risen dramatically in recent years. . ... Despite the challenges, some cell and gene therapy companies have already launched products based on annuity pricing models.
13. SORAYA BEKKALI. Gene therapy pioneer. Cell and gene therapy is definitely the most exciting development in biopharma research, promising breakthroughs and even cures for previously untreatable diseases. ... Eye diseases are at the forefront of the
More from intelligence
Approximately 2 fully matching, plus 13 partially matching documents found.
Dr Germano Ferrari. His most recent role was as a programme manager at the UK’s Cell and Gene Therapy Catapult where he helped develop commercialisation pathways for several pre-clinical ... Dr Ferrari said “We have now reached a turning point where
GSK’s CSO cell and gene therapy heads for the exit, Gelesis adds to company, Abcam appoints Peter Allen and Joseph Swedish joins Mesoblast’s board. ... be a global leader in the development and commercialisation of cell and gene therapy treatments.”
He said: “Now is an exciting time to be joining Orchard as the cell and gene therapy field is advancing successfully. ... The clinical data we’ve seen to date with Orchard’s therapy for ADA-SCID is exceptional, and the company has assembled and
chief scientific officer, global business development and licensing, and chief scientific officer for its cell and gene therapy unit. ... and Genetic Therapy Inc. Lou Panaccio, chairman of Avita, said: “Mike’s expertise across the value chain in cell
He said: “I am excited and honoured to be able to contribute to the company that operates successfully for almost 10 years in the fast-moving field of cell and gene ... successful track record as one of the leading CDMOs for complex cell and gene
More from appointments
Approximately 1 fully matching, plus 7 partially matching documents found.
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... outcomes. This is truly unprecedented and more involved than previous solutions to the challenges facing a registry. Early
A number of current therapeutic approaches – such as gene editing, gene therapy, and stem-cell therapy – were not in existence when many healthcare professionals (HCPs) underwent their training, so there is ... We have correspondingly invested in
the cost curve to accommodate new and expensive cell and gene therapies. In addition to this, insurance plans demand lower co-pays for hospital costs i.e. ... can. Potential methods of payment proposed for expensive cell and gene therapies include:.
Directors Brett Gardiner and Rachel Howard attended the World Pharma Pricing and Market Access Congress in Amsterdam in March. ... A major focus was the new challenges facing Health Technology Assessment (HTA) organizations in view of the expanding
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’. ... Precision medicine with precision management and precision pricing; ensuring affordability in the cell and gene therapy era.
More from PMHub
Approximately 0 fully matching, plus 9 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...